Yıl: 2021 Cilt: 36 Sayı: 2 Sayfa Aralığı: 215 - 221 Metin Dili: Türkçe DOI: 10.5505/tjo.2021.2601 İndeks Tarihi: 04-06-2022

Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Öz:
Astragalus membranaceus root extract (AMe) has been shown to have immunomodulatory effects on macrophages and Th1 type immune responses. Our goal was to determine whether AMe improves the overall survival (OS) of patients with metastatic non-small cell lung cancer (NSCLC). METHODS The medical charts of metastatic NSCLC were retrospectively reviewed. Histological subtype, performance status, age, gender, smoking status, comorbidities, chemotherapeutics, and erlotinib that were part of any type of treatment were recorded. RESULTS The median age of the patients was 61. The median follow-up period was longer for Group A (AMe users) than Group C (control group) (18 vs. 11 months, p<0.001). At the time of analysis, 83.8% of the patients had died. Univariate analysis showed that OS was significantly longer in Group A than Group C (21±4.2 vs. 11±0.9 months, p=0.004). In addition to AMe usage, female gender, smoking status, presence of hypertension, and erlotinib usage also had significant impacts on OS (p<0.05 for all variables). The multivariate analysis showed that only AMe (hazard ratio [HR]: 0.46, 95% CI: 0.27-0.76, p=0.003) and erlotinib (HR: 0.45, 95% CI: 0.22-0.89, p=0.02) usage were correlated with significantly longer OS. CONCLUSION Taking AMe during systemic anti-cancer treatment may significantly prolong OS of patients with metastatic NSCLC.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):192–237.
  • 2. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN guidelines insights: nonsmall cell lung cancer, version 5. 2018. J Natl Compr Canc Netw 2018;16(7):807–21.
  • 3. Cho WC, Leung KN. In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol 2007;113(1):132–41.
  • 4. Auyeung KK, Woo PK, Law PC, Ko JK. Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. J Ethnopharmacol 2012;141(2):635–41.
  • 5. Ren S, Zhang H, Mu Y, Sun M, Liu P. Pharmacological effects of Astragaloside IV: a literature review. J Tradit Chin Med 2013;33(3):413–6.
  • 6. Block KI, Mead MN. Immune System Effects of Echinacea, Ginseng, and Astragalus: A Review. Integr Cancer Ther. 2003;2(3):247–67.
  • 7. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small- cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006;24(3):419–30.
  • 8. He CS, Liu YC, Xu ZP, Dai PC, Chen XW, Jin DH. Astragaloside IV enhances cisplatin chemosensitivity in non-small cell lung cancer cells through inhibition of B7-H3. Cell Physiol Biochem 2016;40(5):1221–9.
  • 9. Wang SF, Wang Q, Jiao LJ, Huang YL, Garfield D, Zhang J, et al. Astragalus-containing traditional Chinese medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis. Curr Oncol. 2016;23(3):188–95.
  • 10. Cheng YY, Hsieh CH, Tsai TH. Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics. J Food Drug Anal 2018;26(2s):88–95.
  • 11. Sun Y, Hersh EM, Lee SL, McLaughlin M, Loo TL, Mavligit GM. Preliminary observations on the effects of the Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on lymphocyte blastogenic responses. J Biol Response Mod 1983;2(3):227–37.
  • 12. Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun 2004;320(4):1103–11.
  • 13. Zhou X, Liu Z, Long T, Zhou L, Bao Y. Immunomodulatory effects of herbal formula of Astragalus polysaccharide (APS) and polysaccharopeptide (PSP) in mice with lung cancer. Int J Biol Macromol 2018;106:596–601.
  • 14. Zhao LH, Ma ZX, Zhu J, Yu XH, Weng DP. Characterization of polysaccharide from Astragalus radix as the macrophage stimulator. Cell Immunol 2011;271(2):329–34.
  • 15. Zhou R, Chen H, Chen J, Chen, X, Wen, Y, Xu L, et al. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med 2018;18(1):83.
  • 16. Auyeung KK, Mok NL, Wong CM, Cho CH, Ko JK. Astragalus saponins modulate mTOR and ERK signaling to promote apoptosis through the extrinsic pathway in HT-29 colon cancer cells. Int J Mol Med 2010;26(3):341–9.
  • 17. Ohkawara S, Okuma Y, Uehara T, Yamagishi T, Nomura Y. Astrapterocarpan isolated from Astragalus membranaceus inhibits proliferation of vascular smooth muscle cells. Eur J Pharmacol 2005;525(1- 3):41–7.
  • 18. Cassileth BR, Rizvi N, Deng G, Yeung KS, Vickers A, Guillen S, et al. Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cancer Chemother Pharmacol 2009;65(1):67–71.
  • 19. Liu ZL, Zhu WR, Zhou WC, Ying HF, Zheng L, Guo YB, et al. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis. J Integr Med 2014;12(4):346–58.
  • 20. Dai PC, Liu DL, Zhang L, Ye J, Wang Q, Zhang HW, et al. Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6. Tumour Biol 2017;39(4):1010428317697555.
  • 21. Ohnuma Y, Toda M, Fujita M, Hosono K, Suzuki T, Ogawa Y, et al. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother 2009;63(2):136–45.
  • 22. Chauhan VP, Martin JD, Liu H, Liu H, Lacorre DA, Jain SR, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 2013;4:2516.
  • 23. Aydiner A, Ciftci R, Sen F. Renin-angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib. Medicine (Baltimore) 2015;94(22):e887.
  • 24. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61(4):344–9.
APA AK N, ÇİFTÇİ R, CABIOĞLU N, Aydiner A (2021). Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. , 215 - 221. 10.5505/tjo.2021.2601
Chicago AK Naziye,ÇİFTÇİ Rümeysa,CABIOĞLU Neslihan,Aydiner Adnan Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. (2021): 215 - 221. 10.5505/tjo.2021.2601
MLA AK Naziye,ÇİFTÇİ Rümeysa,CABIOĞLU Neslihan,Aydiner Adnan Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. , 2021, ss.215 - 221. 10.5505/tjo.2021.2601
AMA AK N,ÇİFTÇİ R,CABIOĞLU N,Aydiner A Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. . 2021; 215 - 221. 10.5505/tjo.2021.2601
Vancouver AK N,ÇİFTÇİ R,CABIOĞLU N,Aydiner A Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. . 2021; 215 - 221. 10.5505/tjo.2021.2601
IEEE AK N,ÇİFTÇİ R,CABIOĞLU N,Aydiner A "Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study." , ss.215 - 221, 2021. 10.5505/tjo.2021.2601
ISNAD AK, Naziye vd. "Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study". (2021), 215-221. https://doi.org/10.5505/tjo.2021.2601
APA AK N, ÇİFTÇİ R, CABIOĞLU N, Aydiner A (2021). Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. Türk Onkoloji Dergisi, 36(2), 215 - 221. 10.5505/tjo.2021.2601
Chicago AK Naziye,ÇİFTÇİ Rümeysa,CABIOĞLU Neslihan,Aydiner Adnan Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. Türk Onkoloji Dergisi 36, no.2 (2021): 215 - 221. 10.5505/tjo.2021.2601
MLA AK Naziye,ÇİFTÇİ Rümeysa,CABIOĞLU Neslihan,Aydiner Adnan Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. Türk Onkoloji Dergisi, vol.36, no.2, 2021, ss.215 - 221. 10.5505/tjo.2021.2601
AMA AK N,ÇİFTÇİ R,CABIOĞLU N,Aydiner A Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. Türk Onkoloji Dergisi. 2021; 36(2): 215 - 221. 10.5505/tjo.2021.2601
Vancouver AK N,ÇİFTÇİ R,CABIOĞLU N,Aydiner A Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study. Türk Onkoloji Dergisi. 2021; 36(2): 215 - 221. 10.5505/tjo.2021.2601
IEEE AK N,ÇİFTÇİ R,CABIOĞLU N,Aydiner A "Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study." Türk Onkoloji Dergisi, 36, ss.215 - 221, 2021. 10.5505/tjo.2021.2601
ISNAD AK, Naziye vd. "Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study". Türk Onkoloji Dergisi 36/2 (2021), 215-221. https://doi.org/10.5505/tjo.2021.2601